RVRC Revium Rx.

NEUTRAL Impact: 3/10 8-K
Horizon months Filed Apr 20, 2026 Processed 1mo ago SEC 0001213900-26-045633
8-K context-dependent: Items 5.02
Latest settled — T+20d
RVRC ▲ 0.00% at T+20d
NEUTRAL call ✗ call lost 0.00% · α vs SPY -4.92% · entry $1.67 → $1.67
Next anchor: T+60d in 4w
Last close $1.67 (close Jun 12) · -0.00% from $1.67 entry
Entry anchored
Apr 20, 2026
via day open
T+1d
0.00%
call 0.00% · α -1.02%
$1.67
settled 8w ago
T+5d
0.00%
call 0.00% · α -1.08%
$1.67
settled 7w ago
T+20d
0.00%
call 0.00% · α -4.92%
$1.67
settled 28d ago
T+60d
call — · α —
in 4w

Price Chart

Loading chart...

Executive Summary

Revium Rx appointed Amir Avraham as permanent CEO effective February 1, 2026, and Shlomi Schwartzblat as a director and chairman of the board. Avraham's employment agreement includes a monthly salary of NIS 55,000, eligibility for cash bonuses totaling up to $50,000, and stock options to purchase 1.9 million shares of common stock, subject to vesting and performance milestones.

Actionable Insight

Monitor for future funding announcements as the $50,000 bonus is tied to raising $5M in equity investments within 18 months; watch for potential share dilution from the 1.9 million stock options granted to the new CEO.

Key Facts

  • Amir Avraham appointed permanent CEO effective February 1, 2026, after serving as interim CEO since May 22, 2025
  • Shlomi Schwartzblat appointed as director and chairman of the board
  • Avraham's monthly salary set at NIS 55,000 (approximately $15,000 USD at current exchange rates)
  • Avraham eligible for $50,000 cash bonus upon raising $5M in equity investments within 18 months of February 1, 2026
  • Avraham granted options to purchase 1.9 million shares (1.3M initial grant, 300K for investment milestone, 300K for M&A milestone)
  • Employment agreement includes 90-day notice period and 12-month non-compete clause

Financial Impact

Compensation package includes base salary of approximately $180,000 annually, potential $50,000 cash bonus, and stock options for 1.9 million shares subject to vesting and performance conditions

dilutioncompensationgovernance

Risk Factors

  • Potential dilution from issuance of up to 1.9 million stock options
  • CEO's compensation is tied to fundraising success, which could incentivize dilutive capital raises

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001213900-26-045633
Document: ea0287042-8k_revium.htm0001213900-26-045633
Document: 0001213900-26-045633-index-headers.html0001213900-26-045633
Document: 0001213900-26-045633-index.html0001213900-26-045633
Document: 0001213900-26-045633.txt0001213900-26-045633
2 reports for RVRC
Performance horizon
Filters
Rows
Reports for RVRC — sortable, filterable
Type Now
Jun 1, 2026
13d ago
8-K
NEUTRAL ★ 2/10
$1.67 $1.67· 0.00%▲ +2.75%$1.67 (−0.00%)
Apr 20, 2026
7w ago
8-K
NEUTRAL ★ 3/10
$1.67 $1.67· 0.00%▼ −1.08%$1.67 (−0.00%)
Showing 2 of 2

US Market Status

Market Closed — Opens in 5h 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access